🔗 Share this article

Given that America continues making historic adjustments to its vaccination guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about Covid shots in the pandemic and has concentrated on alleged deaths after Covid immunization in her recent time at the FDA.

Planned Changes to Pediatric Vaccine Schedule

Health officials were set to announce major changes to the childhood immunization program recently, synchronizing the US with the Danish national calendar, according to reports – a significant shift that would place the US out of step with much of the world with insufficient data for improved outcomes. The announcement has been postponed until the coming year.

In place of the top vaccines chief, Høeg is scheduled to speak at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to lead the center this calendar year.

A Shift at the FDA

The acting appointment may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting specific pediatric vaccine recommendations in the US to become more like Denmark, a country with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

So far comments, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Expertise

Dr. Høeg has no apparent track record in medication creation, approval processes or administrative roles, which has been customary for previous leaders of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past directors of CBER would “grasp legal statutes and the research of medication creation”, said a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that previous people who headed the center have had.”

The drug center has an vast portfolio at the FDA, she emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic program authorizes thousands of generic medications. There is also a biologic copycat branch, over-the-counter program and more, and all of those have to be looked after,” Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a substantial management aspect to the position, which manages in excess of 5,000 personnel. “It is a huge leadership role, if you do it right,” she said.

Response and Disputed Programs

When asked about questions about Høeg’s qualifications and whether this assignment represents greater collaboration among regulatory chiefs on immunizations, a press secretary stated that the “questions stem from incorrect premises”.

“Her experience aligns with the duties of her job,” the spokesperson said, citing the period Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the agency head's recently launched expedited review system, a disputed rapid medication authorization process that reportedly concerned her preceding directors. “By what process are these medications being chosen for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed regulations of all drugs, with the exception of vaccines.”

Documented History on Immunizations

With immunizations, Dr. Høeg has a clearer, if problematic, track record, critics observe. She authored a study using unconfirmed volunteer-provided data to determine the rate of myocarditis following COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the current federal leadership featured altering guidelines for new vaccines and ending “unnecessary” immunizations, she remarked after the election on a podcast. At the FDA, Høeg has according to sources suggested excluding young men from obtaining Covid vaccines.

“She’s an all-around dogmatist who commences with her conclusions and works backwards to retrofit the science in a extremely misleading, fraudulent fashion,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other dissenters, {like|